title: Role of darunavir in the management of HIV infection.
abstract: There is an ongoing need for potent antiretroviral therapies to deal with the increasing pool of treatment-experienced patients with multiple drug resistance. The last few years have seen the arrival of 2 new and very potent protease inhibitors - darunavir and tipranavir - alongside 2 whole new classes of anti-HIV agents - the integrase inhibitors and chemokine receptor CCR5 antagonists. This review focuses on the role of darunavir in managing HIV infection, with an emphasis on darunavir's exceptional resistance profile and related clinical effectiveness, pharmacokinetics, tolerability and toxicity data. Darunavir in combination with the pharmacokinetic booster ritonavir has proved to be very effective in the treatment of highly treatment-experienced HIV patients with multiple drug resistance. The favorable tolerability and toxicity profile alongside the drug's high genetic barrier to the development of resistance prompted approval of darunavir for HIV-treatment naïve patients. Furthermore, the paradigm of treating HIV with a combination of anti-HIV agents is currently being challenged by ongoing darunavir monotherapy trials and these preliminary data will be discussed.
authors.affiliation: The Mortimer Market Centre, Camden PCT, London WC1E 6JB.
authors.forename: R Monica
authors.initials: RM
authors.lastname: Lascar
authors.forename: Paul
authors.initials: P
authors.lastname: Benn
references.citation: J Virol. 2004 Nov;78(21):12012-21
references.pmid: 15479840
references.citation: J Med Chem. 2006 Feb 23;49(4):1379-87
references.pmid: 16480273
references.citation: JAMA. 1998 Jun 24;279(24):1977-83
references.pmid: 9643862
references.citation: AIDS. 2004 Aug 20;18(12):1653-60
references.pmid: 15280776
references.citation: Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21
references.pmid: 15917527
references.citation: Biochim Biophys Acta. 2000 Mar 7;1477(1-2):189-214
references.pmid: 10708858
references.citation: AIDS Clin Care. 2006 Aug;18(8):71
references.pmid: 16906668
references.citation: Biochemistry. 1997 Sep 2;36(35):10696-708
references.pmid: 9271500
references.citation: HIV Med. 2009 May;10(5):318-27
references.pmid: 19210693
references.citation: Acc Chem Res. 2008 Jan;41(1):78-86
references.pmid: 17722874
references.citation: Protein Sci. 2000 Oct;9(10):1898-904
references.pmid: 11106162
references.citation: Methods Enzymol. 1994;241:279-301
references.pmid: 7854182
references.citation: Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:37-42
references.pmid: 19195458
references.citation: Bioorg Med Chem. 2007 Dec 15;15(24):7576-80
references.pmid: 17900913
references.citation: AIDS. 2000 Jan 28;14(2):141-9
references.pmid: 10708284
references.citation: Lancet. 2007 Jul 7;370(9581):49-58
references.pmid: 17617272
references.citation: HIV Clin Trials. 2007 Sep-Oct;8(5):303-10
references.pmid: 17956831
references.citation: HIV Clin Trials. 2007 Jul-Aug;8(4):213-20
references.pmid: 17720661
references.citation: J Mol Biol. 2006 Oct 13;363(1):161-73
references.pmid: 16962136
references.citation: HIV Clin Trials. 2007 May-Jun;8(3):121-31
references.pmid: 17621459
references.citation: Drugs. 2009;69(4):477-503
references.pmid: 19323590
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):1003-10
references.pmid: 16511767
references.citation: AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61
references.pmid: 19320601
references.citation: AIDS. 2009 Aug 24;23(13):1679-88
references.pmid: 19487905
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4315-9
references.pmid: 18809940
references.citation: Antivir Ther. 2008;13(1):1-13
references.pmid: 18389894
references.citation: J Virol. 2007 Dec;81(24):13845-51
references.pmid: 17928344
references.citation: HIV Med. 2006 Nov;7(8):487-503
references.pmid: 17105508
references.citation: J Med Chem. 2005 Mar 24;48(6):1965-73
references.pmid: 15771440
references.citation: N Engl J Med. 1998 Mar 26;338(13):853-60
references.pmid: 9516219
references.citation: AIDS Res Hum Retroviruses. 2008 Mar;24(3):379-88
references.pmid: 18327986
references.citation: AIDS. 2009 Jul 31;23(12):1539-46
references.pmid: 19487910
references.citation: AIDS. 2008 Jul 31;22(12):1389-97
references.pmid: 18614861
references.citation: Structure. 2002 Mar;10(3):369-81
references.pmid: 12005435
references.citation: Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9
references.pmid: 14506019
references.citation: Vox Sang. 2002 Aug;83 Suppl 1:23-6
references.pmid: 12617097
references.citation: HIV Med. 2009 Jan;10(1):19-27
references.pmid: 19018880
references.citation: J Mol Biol. 2008 Dec 5;384(1):178-92
references.pmid: 18834890
references.citation: Bioorg Med Chem Lett. 1998 Mar 17;8(6):687-90
references.pmid: 9871583
references.citation: Lancet. 2007 Apr 7;369(9568):1169-78
references.pmid: 17416261
references.citation: JAMA. 2006 Aug 16;296(7):827-43
references.pmid: 16905788
references.citation: Expert Opin Pharmacother. 2007 Apr;8(6):839-50
references.pmid: 17425479
references.citation: AIDS. 2008 Nov 30;22(18):2509-15
references.pmid: 19005274
references.citation: J Biol Chem. 2007 Sep 28;282(39):28709-28720
references.pmid: 17635930
references.citation: J Med Chem. 2005 Mar 24;48(6):1813-22
references.pmid: 15771427
references.citation: AIDS Res Hum Retroviruses. 2008 Oct;24(10):1275-80
references.pmid: 18844462
references.citation: J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):24-31
references.pmid: 17621237